{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 40,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a grid of metrics to define the addressable market and clinical success thresholds.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/22",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.11,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "1L, first line; 2L+, second line or greater; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOC, standard of care.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb55100c-4a3c-4ce7-a8a8-81747a445abd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.71,
        "y": 0.25
      },
      "kind": "list",
      "text": "Available Treatment: 1L: Chemo + ICI 50% ORR; 2L+: SOC 10% - 20% ORR",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf41feb7-0eea-44b8-a1df-1cc624df0c34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "list",
      "text": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%. Internal success threshold: 2L+ ORR of ~15% - 20% (approvability bar based on precedent); 20%+ (commercially relevant) following BA3011 monotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2262ce9-9228-4113-bd57-7b7ae938a2ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.03,
        "y": 0.442
      },
      "kind": "metric",
      "text": "2L+ despite advances in 1L care, majority of patients progress",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87fc9fc6-86bf-42af-bffc-b3b3eedcb3e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.03,
        "y": 0.188
      },
      "kind": "metric",
      "text": ">540K people in the U.S. living with lung cancer",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1990a92-7bca-4e9a-85e4-8e9939f69376",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.37,
        "y": 0.442
      },
      "kind": "metric",
      "text": "~75% non-squamous cell represents majority of patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7658d20-7615-4cd2-b2e4-4dc4a268ad11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.37,
        "y": 0.188
      },
      "kind": "metric",
      "text": "~200K newly diagnosed patients / year (U.S.) – majority advanced / metastatic",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fef1bd36-9d19-4d71-b314-4c94f4d49c84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.58,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Potential market opportunity in metastatic NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b5ae4df-caae-42eb-941a-b199ebc0859f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e9f27a62-e4a4-4938-af0c-d29e84fd6ebf",
      "evidence": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%.",
      "confidence": 0.7
    },
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "b0d509be-e63f-4ab7-994f-3c2a07941549",
      "evidence": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}